© Reuters. FILE PHOTO: An Amgen signal is seen on the firm’s workplace in South San Francisco, California October 21, 2013. The biopharmaceutical firm stories earnings on Tuesday. REUTERS/Robert Galbraith/File Photograph
(Reuters) -Amgen Inc will purchase uncommon illness drugmaker Horizon Therapeutics (NASDAQ:) Plc for $26.40 billion, giving the biotech firm entry to blockbuster thyroid eye illness drug Tepezza, the businesses stated on Monday.
The deal shall be Amgen (NASDAQ:)’s largest but and can add a number of accredited medication to the corporate’s portfolio together with Krystexxa used for the therapy of gout that isn’t managed by different medicines.
The acquisition may assist Amgen counter the impression from rising competitors for its top-selling arthritis drug, Enbrel, from newer branded therapies and anticipated expiry of patents for the remedy in 2029.
